Search

Your search keyword '"Nador, Guido"' showing total 31 results
Start Over Author "Nador, Guido"
31 results on '"Nador, Guido"'

1. Elranatamab efficacy in MagnetisMM-3 compared with real-world control arms in triple-class refractory multiple myeloma

Author

Costa, Luciano J, primary, LeBlanc, Thomas W, additional, Tesch, Hans, additional, Sonneveld, Pieter, additional, Kyle, Ryan P, additional, Sinyavskaya, Liliya, additional, Hlavacek, Patrick, additional, Meche, Aster, additional, Ren, Jinma, additional, Schepart, Alex, additional, Aydin, Didem, additional, Nador, Guido, additional, and DiBonaventura, Marco daCosta, additional

Published
2024
Full Text
View/download PDF

5. A matching-adjusted indirect comparison of the efficacy of elranatamab versus physician's choice of treatment in patients with triple-class exposed/refractory multiple myeloma.

Author

Mol, Isha, Hu, Yannan, LeBlanc, Thomas W., Cappelleri, Joseph C., Chu, Haitao, Nador, Guido, Aydin, Didem, Schepart, Alex, and Hlavacek, Patrick

Subjects
MULTIPLE myeloma, PHYSICIANS, BISPECIFIC antibodies, ODDS ratio, LOGISTIC regression analysis
Abstract

For patients with triple-class exposed/refractory multiple myeloma (TCE/R MM), prognosis is poor and effective treatment options are limited. Elranatamab is a novel B-cell maturation antigen (BCMA)- and CD3-directed bispecific antibody which was approved by the US Food and Drug Administration in August 2023 and demonstrated safety and efficacy in patients with TCE/R MM in the phase 2, single-arm MagnetisMM-3 trial (NCT04649359). To compare the effectiveness of elranatamab vs physician's choice of treatment (PCT) in the absence of head-to-head comparative data, a matching-adjusted indirect comparison (MAIC) was conducted. Individual patient data from MagnetisMM-3 (Cohort A [BCMA-naïve] N = 123, 14.7 months of follow-up) were reweighted to match published summary data from two real-world studies of PCT in patients with TCE/R MM (LocoMMotion and MAMMOTH) using a propensity score-type logistic regression. Unanchored MAIC analyses were conducted according to National Institute for Health and Care Excellence (NICE) Decision Support Unit (DSU) 18 guidance. Compared with PCT in LocoMMotion, elranatamab was associated with a significantly higher objective response rate (ORR rate difference: 37.52; 95% CI 26.20–48.83; odds ratio: 4.85; 95% CI 2.85–8.23) and complete or stringent complete response rate (≥CR rate difference: 42.29; 95% CI 31.84–52.74; odds ratio: 184.01; 95% CI 24.66–1372.86), longer progression-free survival (PFS HR 0.32; 95% CI 0.20–0.49), and overall survival (OS HR 0.62; 95% CI 0.40–0.94). Compared with PCT in MAMMOTH, elranatamab was associated with significantly higher ORR (rate difference: 28.14; 95% CI 16.77–39.52; odds ratio: 3.24; 95% CI 1.98–5.32) and ≥ CR (rate difference: 26.22; 95% CI 16.40–36.05; odds ratio: 5.48; 95% CI 2.88–10.44), as well as longer PFS (HR 0.25; 95% CI 0.17–0.37) and OS (HR 0.49; 95% CI 0.33–0.71). Sensitivity analysis results were consistent with the base case. In the MAIC, elranatamab was consistently associated with improved rates and depth of response and significantly longer PFS and OS versus PCT in LocoMMotion and MAMMOTH. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. P-249 The association between age, performance status, frailty and outcomes in real-world clinical practice among patients with triple-class exposed multiple myeloma

Author

Meche, Aster, primary, Rondeau, Felix, additional, Johnson, Sarasa, additional, Ren, Jinma, additional, Schepart, Alexander, additional, Hlavacek, Patrick, additional, Farrell, James, additional, Aydin, Didem, additional, Nador, Guido, additional, and DiBonaventura, Marco, additional

Published
2023
Full Text
View/download PDF

7. P-248 Real-world outcomes of triple-class exposed multiple myeloma patients by treatment experience: the assocaition of prior lines and penta-refractoriness with progression-free and overall survival

Author

Meche, Aster, primary, Rondeau, Felix, additional, Faucher, Ariane, additional, Ren, Jinma, additional, Schepart, Alexander, additional, Hlavacek, Patrick, additional, Farrell, James, additional, Aydin, Didem, additional, Nador, Guido, additional, and DiBonaventura, Marco, additional

Published
2023
Full Text
View/download PDF

9. Prospective Assessment of Tumour Burden and Bone Disease in Plasma Cell Dyscrasias Using DW-MRI and Exploratory Bone Biomarkers

Author

Agarwal, Gaurav, primary, Nador, Guido, additional, Varghese, Sherin, additional, Getu, Hiwot, additional, Palmer, Charlotte, additional, Watson, Edmund, additional, Pereira, Claudio, additional, Sallemi, Germana, additional, Partington, Karen, additional, Patel, Neel, additional, Soundarajan, Rajkumar, additional, Mills, Rebecca, additional, Brouwer, Richard, additional, Maritati, Marina, additional, Shah, Aarti, additional, Peppercorn, Delia, additional, Oppermann, Udo, additional, Edwards, Claire M., additional, Rodgers, Christopher T., additional, Javaid, Muhammad Kassim, additional, Gooding, Sarah, additional, and Ramasamy, Karthik, additional

Published
2022
Full Text
View/download PDF

10. P-043: Prospective assessment of myeloma tumour burden and bone disease using DW-MRI and exploratory bone biomarkers

Author

Agarwal, Gaurav, primary, Nador, Guido, additional, Varghese, Sherin, additional, Getu, Hiwot, additional, Palmer, Charlotte, additional, Watson, Edmund, additional, Rodgers, Chris, additional, Pereira, Claudio, additional, Sallemi, Germana, additional, Partington, Karen, additional, Patel, Neel, additional, Soundarajan, Raj, additional, Mills, Rebecca, additional, Brouwer, Richard, additional, Maritati, Marina, additional, Shah, Aarti, additional, Peppercorn, Delia, additional, Oppermann, Udo, additional, Edwards, Claire, additional, Javaid, M Kassim, additional, Gooding, Sarah, additional, and Ramasamy, Karthik, additional

Published
2022
Full Text
View/download PDF

12. Prospective Assessment of Tumour Burden and Bone Disease in Plasma Cell Dyscrasias Using DW-MRI and Exploratory Bone Biomarkers.

Author

Agarwal, Gaurav, Nador, Guido, Varghese, Sherin, Getu, Hiwot, Palmer, Charlotte, Watson, Edmund, Pereira, Claudio, Sallemi, Germana, Partington, Karen, Patel, Neel, Soundarajan, Rajkumar, Mills, Rebecca, Brouwer, Richard, Maritati, Marina, Shah, Aarti, Peppercorn, Delia, Oppermann, Udo, Edwards, Claire M., Rodgers, Christopher T., and Javaid, Muhammad Kassim

Subjects
*BONE diseases, *BIOMARKERS, *PARAPROTEINEMIA, *MAGNETIC resonance imaging, *CANCER patients, *LONGITUDINAL method, *DISEASE complications
Abstract

Simple Summary: Whilst multiple myeloma (MM) remains incurable, two clinical priorities are to prolong remission and reduce complications, of which fragility fractures are a major source of morbidity. To this end, there is the need to develop biomarkers that can accurately track tumour burden and bone loss to guide treatment decisions. Here, we conducted a pilot feasibility study exploring the value of novel serum bone turnover and plasma cell burden markers and Diffusion-Weighted Magnetic Resonance Imaging (DW-MRI) when added to standard clinical assessment in patients with MM, monoclonal gammopathy of undetermined significance (MGUS) and smouldering MM (SMM). We show serum DKK1 and BCMA as possible correlates of tumour burden, and that serum sclerostin may correlate with bone mineral density. Furthermore, we validate DW-MRI in longitudinal assessment of tumour volume. Our study highlights emerging serum and radiological biomarkers for assessment of tumour burden and bone loss, which require further study in larger cohorts to validate these findings and understand their clinical utility. Novel biomarkers for tumour burden and bone disease are required to guide clinical management of plasma cell dyscrasias. Recently, bone turnover markers (BTMs) and Diffusion-Weighted Magnetic Resonance Imaging (DW-MRI) have been explored, although their role in the prospective assessment of multiple myeloma (MM) and monoclonal gammopathy of undetermined significance (MGUS) is unclear. Here, we conducted a pilot observational cohort feasibility study combining serum BTMs and DW-MRI in addition to standard clinical assessment. Fifty-five patients were recruited (14 MGUS, 15 smouldering MM, 14 new MM and 12 relapsed MM) and had DW-MRI and serum biomarkers (P1NP, CTX-1, ALP, DKK1, sclerostin, RANKL:OPG and BCMA) measured at baseline and 6-month follow-up. Serum sclerostin positively correlated with bone mineral density (r = 0.40−0.54). At baseline, serum BCMA correlated with serum paraprotein (r = 0.42) and serum DKK1 correlated with serum free light chains (r = 0.67); the longitudinal change in both biomarkers differed between International Myeloma Working Group (IMWG)-defined responders and non-responders. Myeloma Response Assessment and Diagnosis System (MY-RADS) scoring of serial DW-MRI correlated with conventional IMWG response criteria for measuring longitudinal changes in tumour burden. Overall, our pilot study suggests candidate radiological and serum biomarkers of tumour burden and bone loss in MM/MGUS, which warrant further exploration in larger cohorts to validate the findings and to better understand their clinical utility. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

16. Multiple myeloma increases nerve growth factor and other pain-related markers through interactions with the bone microenvironment

Author

Olechnowicz, Sam W. Z., primary, Weivoda, Megan M., additional, Lwin, Seint T., additional, Leung, Szi K., additional, Gooding, Sarah, additional, Nador, Guido, additional, Javaid, Muhammed Kassim, additional, Ramasamy, Karthik, additional, Rao, Srinivasa R., additional, Edwards, James R., additional, and Edwards, Claire M., additional

Published
2019
Full Text
View/download PDF

18. Elective Vs Non-Elective Hospital Admissions By Patients with Multiple Myeloma in England 2014 - 2018

Author

Ramasamy, Karthik, primary, Kolovos, Spyros, additional, Nador, Guido, additional, Finley, Rosemarie, additional, Streetly, Matthew, additional, Kishore, Bhuvan, additional, Rabin, Neil K, additional, Chantry, Andrew D, additional, Yong, Kwee, additional, Ashcroft, John, additional, Bowcock, Stella, additional, Drayson, Mark T, additional, Prieto-Alhambra, Daniel, additional, Cooper, Cyrus, additional, Javaid, Muhammad Kassim, additional, and Pinedo-Villanueva, Rafael, additional

Published
2018
Full Text
View/download PDF

23. Corrigendum to ‘Hematological improvement during iron-chelation therapy in myelodysplastic syndromes: The experience of the “Rete Ematologica Lombarda”’ [Leuk Res 37 (2013) 1233–1240]

Author

Molteni, Alfredo, primary, Riva, Marta, additional, Pellizzari, Annamaria, additional, Borin, Lorenza, additional, Freyrie, Alessandra, additional, Greco, Rosa, additional, Ubezio, Marta, additional, Bernardi, Massimo, additional, Fariciotti, Alessio, additional, Nador, Guido, additional, Nichelatti, Michele, additional, Ravano, Emanuele, additional, and Morra, Enrica, additional

Published
2014
Full Text
View/download PDF

24. A Phase II Multi-Center Trial Of Pentostatin Plus Cyclophosphamide With Ofatumumab (PCO) In Older Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients

Author

Montillo, Marco, primary, Rossi, Davide, additional, Motta, Marina, additional, Quaresmini, Giulia, additional, Rossi, Marianna, additional, Coscia, Marta, additional, Anastasia, Antonella, additional, Rossini, Fausto, additional, Cortelezzi, Agostino, additional, Nador, Guido, additional, Scarfò, Lydia, additional, Cairoli, Roberto, additional, Ceggio, Daniela Dal, additional, De Paoli, Lorenzo, additional, Morra, Enrica, additional, Rambaldi, Alessandro, additional, Orlandi, Ester, additional, Massaia, Massimo, additional, and Tedeschi, Alessandra, additional

Published
2013
Full Text
View/download PDF

26. Prognostic value of circulating CD34+ cells in myelodysplastic syndromes

Author

Cesana, Clara, primary, Klersy, Catherine, additional, Brando, Bruno, additional, Nosari, Annamaria, additional, Scarpati, Barbara, additional, Scampini, Linda, additional, Molteni, Alfredo, additional, Nador, Guido, additional, Santoleri, Luca, additional, Formenti, Marta, additional, Valentini, Marina, additional, Mazzone, Antonino, additional, Morra, Enrica, additional, and Cairoli, Roberto, additional

Published
2008
Full Text
View/download PDF

27. Prospective monocentric study of non-tunnelled central venous catheter-related complications in hematological patients

Author

Nosari, Anna Maria, primary, Nador, Guido, additional, Gasperi, Andrea De, additional, Ortisi, Giuseppe, additional, Volonterio, Alberto, additional, Cantoni, Silvia, additional, Nichelatti, Michele, additional, Marbello, Laura, additional, Mazza, Ernestina, additional, Mancini, Valentina, additional, Ravelli, Erica, additional, Ricci, Francesca, additional, Ciapanna, Denis, additional, Garrone, Federica, additional, Gesu, Giovanni, additional, and Morra, Enrica, additional

Published
2008
Full Text
View/download PDF

29. Complications of Central Venous Catheters in Patients with Hematologic Malignancy: Analysis of Risk Factors.

Author

Nosari, Annamaria, primary, Nador, Guido, additional, de Gasperi, Andrea, additional, Michele, Nichelatti, additional, Michela, Anghilieri, additional, Paola, Cozzi, additional, Valentina, Mancini, additional, Camilla, Luchesini, additional, Francesca, Ricci, additional, Dennis, Ciapanna, additional, Erica, Ravelli, additional, Silvia, Cantoni, additional, and Enrica, Morra, additional

Published
2004
Full Text
View/download PDF

30. Prognostic value of circulating CD34+ cells in myelodysplastic syndromes

Author

Cesana, Clara, Klersy, Catherine, Brando, Bruno, Nosari, Annamaria, Scarpati, Barbara, Scampini, Linda, Molteni, Alfredo, Nador, Guido, Santoleri, Luca, Formenti, Marta, Valentini, Marina, Mazzone, Antonino, Morra, Enrica, and Cairoli, Roberto

Subjects
*MYELODYSPLASTIC syndromes, *DYSPLASIA, *BONE marrow diseases, *CELLS
Abstract

Abstract: We studied circulating (C)CD34+ cells by flow cytometry in 96 patients with myelodisplastic syndromes (MDS) at diagnosis, and in a subset of 35 cases during follow-up. CCD34+ counts were stratified within both International Prognostic Scoring System (IPSS) and World Health Organization (WHO) categories. Counts >10/μl were associated with poorer leukemia-free survival, a prognostic value for evolution independent from that of WHO, and a higher progression probability within intermediate-risk IPSS and WHO classes. When serial measurements were performed, counts >10/μl more frequently correlated to evolution. Separating newly diagnosed patients on the basis of 10/μl cut-off of circulating CD34+ cells retains prognostic utility, especially in intermediate-risk MDS. [Copyright &y& Elsevier]

Published
2008
Full Text
View/download PDF

31. A phase II multi-center trial of pentostatin plus cyclophosphamide with ofatumumab in older previously untreated chronic lymphocytic leukemia patients.

Author

Tedeschi A, Rossi D, Motta M, Quaresmini G, Rossi M, Coscia M, Anastasia A, Rossini F, Cortelezzi A, Nador G, Scarfò L, Cairoli R, Frustaci AM, Dalceggio D, Picardi P, De Paoli L, Orlandi E, Rambaldi A, Massaia M, Gaidano G, and Montillo M

Subjects
Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols adverse effects, Cyclophosphamide administration & dosage, Cyclophosphamide adverse effects, Female, Follow-Up Studies, Humans, Leukemia, Lymphocytic, Chronic, B-Cell blood, Leukemia, Lymphocytic, Chronic, B-Cell pathology, Male, Middle Aged, Pentostatin administration & dosage, Pentostatin adverse effects, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Leukemia, Lymphocytic, Chronic, B-Cell drug therapy
Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results